Current Market Update

From Cabot Top Ten Trader Today's weakness cracked the market's intermediate-term uptrend, though because we've been cautious for a while, we're not changing our overall viewpoint—you should be holding some cash and going slow as the market and leaders work through this correction. That we...
Read More

Cabot Stock of the Week 316

Technically, the market is now in an intermediate-term downtrend, which tells us that additional defensive measures would be prudent. In the very short term, however, I expect a bounce from today’s high-profile decline, so I’m mainly holding.
Read More

Moving Gilead (GILD) To SELL

This past Monday, September 14, Turnaround Letter recommended Gilead Sciences (GILD) announced that it will acquire Immunomedics (IMMU) in a $21 billion all-cash deal. The $88/share price is just over a 100% premium to Immunomedics' pre-announcement price. If analysts' estimates that its Trodelvy treatment revenue of...
Read More